Literature DB >> 21964814

Sequential therapy in metastatic renal cell carcinoma: what comes next?

Camillo Porta, Thomas Powles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21964814     DOI： 10.1007/s12032-011-0073-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

Review 1.  Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Authors:  C Porta; G Tortora; C Linassier; K Papazisis; A Awada; D Berthold; J P Maroto; T Powles; M De Santis
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

Review 2.  Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

Authors:  Camillo Porta; Joaquim Bellmunt; Tim Eisen; Cezary Szczylik; Peter Mulders
Journal:  Cancer Treat Rev       Date:  2009-10-09       Impact factor: 12.111

3.  The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.

Authors:  Mhd Y Al-Marrawi; Brian I Rini; Lauren C Harshman; Georg Bjarnason; Lori Wood; Ulka Vaishampayan; Mary MacKenzie; Jennifer J Knox; Neeraj Agarwal; Hulayel Al-Harbi; Christian Kollmannsberger; Min-Han Tan; Sun Young Rha; Frede N Donskov; Scott North; Toni K Choueiri; Daniel Y Heng
Journal:  Target Oncol       Date:  2013-01-09       Impact factor: 4.493
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.